MIRM · Mirum Pharmaceuticals, Inc.
AI read · Good for MIRM
The AI's read
The results could let Mirum offer LIVMARLI to more people with rare liver diseases, if regulators accept the planned filing. The medicine eased itching and lowered bile acids compared with placebo. Diarrhea was more common with treatment, but the report found no new safety concerns.